• Provides DGL in a chewable tablet form, the form associated with the greatest clinical efficacy, as it allows the licorice to be released in the stomach and dispersed/absorbed by the gastric mucosa.
• Offers 400 mg of DGL per tablet, the clinically effective dose.
• Deglycyrrhizination prevents adverse effects associated with licorice consumption.
• Pleasantly flavored tablets for better compliance
• Suitable for vegetarians/vegans

Deglycyrrhizinated licorice, or DGL, has been used clinically for decades, primarily for the treatment of gastroduodenal ulcers. Licorice contains numerous triterpenoids and hundreds of flavonoids that have been shown to inhibit several inflammatory enzymes, including cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). These enzymes decrease the production of several potent inflammatory compounds, including IL-6, prostaglandin E2, thromboxane B2, and leukotriene B4. Importantly, this inhibition is not primarily due to glycyrrhizic acid, the component of licorice that has been removed in DGL and is associated with excess mineralocorticoids and hypertension. Licorice contains numerous active compounds with anti-inflammatory, antimicrobial, and anti-allergic actions, including glabridin and at least seven licochalcones. These compounds have been shown to prevent lipopolysaccharide (LPS)-induced production of inflammatory compounds, inhibit the biofilm formation of yeasts and bacteria, and stimulate antioxidant enzymes.

Clinically, DGL has been shown to be as effective as cimetidine in healing and preventing ulcer recurrence. Furthermore, licorice extracts have been shown to inhibit the adhesion of H. pylori to the gastric mucosa, as well as the growth of antibiotic-resistant strains, suggesting multiple mechanisms of action for its anti-ulcer effect. The use of chewable tablets appears to be necessary for the efficacy of DGL, as they allow for distribution and absorption by the gastric mucosa.